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a b s t r a c t
Mutations in CSF3R (colony-stimulating factor 3 receptor) are frequent oncogenic drivers in chronic
neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). Here we describe a 75 year old
manwho was diagnosed with CSF3R-T618I-positive atypical CML. He presented with leukocytosis, anemia,
and thrombocytopenia and developed massive splenomegaly and severe constitutional symptoms.
Hydroxyurea was given over a 6 month period but failed to provide any measureable clinical beneﬁt.
Eventually, he was treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic
improvement of his blood counts. He also had signiﬁcant reduction of spleen volume and constitutional
symptoms. This case highlights the need for a clinical trial to interrogate JAK1/2 as a potential molecular
target in CNL and aCML in patients with or without CSF3R mutation. A clinical trial evaluating the safety
and efﬁcacy of ruxolitinib for this patient population is registered at ClinicalTrials.gov (NCT02092324).
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Clinically, CNL and aCML are rare leukemias characterized by
varying degrees of leukocytosis, anemia, thrombocytopenia, spleno-
megaly, and constitutional symptoms. Key distinguishing pathologic
features between CNL and aCML are summarized in Table 1 [1]. No
standard of care is established for CNL and aCML and the reported
median overall survival is approximately two years [2]. Recently,
Maxson, et al. reported CSF3R mutations in 90% of patients with
CNL and in 40% of patients with aCML [3]. Subsequent studies
conﬁrmed this high frequency of CSF3R mutation in CNL while
observing a lower frequency in aCML [4]. Mutations in CSF3R generally
occur in the extracellular membrane proximal domain or result in
premature truncation of the cytoplasmic tail. Of note, membrane
proximal mutations are far more common [3]. These membrane
proximal mutations cause signiﬁcant activation of JAK/STAT signaling.
Therefore, targeting of the JAK/STAT pathway may inhibit granulocy-
tic proliferation and provide clinical beneﬁt to patients with CNL or
aCML. Ruxolitinib (Incyte Corporation) is the ﬁrst FDA-approved
JAK1/JAK2 inhibitor with a reported IC50 of 3.3 nM and 2.8 nM,
respectively [5]. In preclinical studies, targeting JAK1/2 with rux-
olitinib signiﬁcantly suppressed CSF3R-T618I-induced malignant
colony growth compared to no drug treatment controls [6]. Trans-
plantation of T618I-CSF3R-expressing mouse bone marrow cells was
sufﬁcient to produce a highly penetrant, lethal neutrophilic leuke-
mia in a mouse model. Treatment of experimental mice with
ruxolitinib provided disease control and improved survival com-
pared to untreated controls [6]. These studies suggest that targeting
JAK1/2 may provide clinical beneﬁt to patients with these rare types
of leukemia.
2. Case study
A 75 year old man with Parkinson's disease was diagnosed with
aCML in April 2013 based on pathologic review of his bone marrow
biopsy and on the ﬁnding of the CSF3R-T618I mutation. According to
old records, leukocytosis (not otherwise speciﬁed) was present as far
back as 2005. His CBC before he began taking hydroxyurea showed
WBC 71.310e3/microliter, ANC 42.110e3/microliter, Hgb 9.8 g/dL,
MCV 98.3 fL, and platelet 9710e3/microliter. His peripheral blood
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showed 12% immature granulocytes and hypogranular neutrophils
and rare pseudo-Pelger–Huet neutrophils. His bone marrow showed
granulocytic hyperplasia (myeloid:erythroid ratio 415:1) and hypo-
lobated megakaryocytes in 30% of megakaryocytes. Peripheral and
marrow blasts were less than 1%. In addition to the CSF3R-T618I
mutation (50% allele frequency), his disease also harbored CBL-I383T
(70% allele frequency) and KDM6A-S114C (100% allele frequency on
one X chromosome) mutations evaluated by massively parallel
sequencing. SETBP1 was wildtype. His disease was characterized by
progressive leukocytosis, anemia, thrombocytopenia, splenomegaly,
and constitutional symptoms. Performance status was ECOG of 3.
Physical exam revealed a chronically ill-appearing, cachectic male with
massive splenomegaly. He began taking hydroxyurea in April 2013 at
1000 mg three times per week and 500 mg four times per week (total
5000 mg per week).
Despite taking hydroxyurea for 6 months, his leukocytosis, sple-
nomegaly, and constitutional symptoms were poorly controlled and
his performance status and overall function had declined even further.
There was little clinical beneﬁt to gain by increasing the hydroxyurea
dose further especially in the setting of severe thrombocytopenia.
Interferon therapywas considered contraindicated due to the potential
for exacerbating his mood disturbances associated with Parkinson's
disease. The patient was eventually prescribed ruxolitinib through his
commercial insurance. Shortly before starting ruxolitinib but while still
on hydroxyurea, his CBC showed WBC 56.010e3/microliter, ANC
48.710e3/microliter, Hgb 8.6 g/dL, MCV 121 fL, and platelet
2810e3/microliter. His spleen volume was 4342 cm3 [3] and his
total symptom score was 164 (total max of 270, MPN-symptom
assessment form [MPN-SAF]) [7].
On December 2013 the patient was started on ruxolitinib 10mg
twice a day (day 0). His dose was increased to 15 mg twice a day on
day þ57 and to 20 mg twice a day on day þ84. He was tapered off
hydroxyurea and was completely off on day þ14. As shown in Fig. 1A,
the WBC and MCV were reduced gradually over 3 months while his
Hgb and platelets steadily increased, indicating improved marrow
function by targeting JAK1/JAK2 signaling and going off hydroxyurea.
His peripheral blood showed reduced immature granulocytes while
the neutrophils displayed increased cytoplasmic granularity/toxic
granulation. His bone marrow had reduced granulocytic hyperplasia
(myeloid:erythroid ratio 10:1) and fewer hypolobated megakaryocytes
compared with the pre-ruxolitinib bone marrow evaluation. Periph-
eral and marrow blasts were less than 1%. In addition, his spleen
volume was reduced by approximately 75% after approximately
3 months of ruxolitinib therapy as shown in Fig. 1B. Furthermore,
his quality of life and total symptom score improved dramatically as
shown in Fig. 1C. As a result of his excellent tolerance and response
to ruxolitinib, his dose was increased further to the target dose of
20 mg twice a day. After this adjustment, his platelets increased
further as shown in Fig. 1A. He has gained weight and his
performance status improved to ECOG of 1. As of this report, he
continues to do well and remains on ruxolitnib 20 mg twice a day.
Interestingly, his dramatic clinical response was not associated with
a reduction in CSF3R-T618I allele frequency based on peripheral
blood studies after approximately 4 months of ruxolitinib treat-
ment. Single colony assays conﬁrmed that the allele frequency was
not signiﬁcantly reduced.
3. Discussion
Here we report a case of CSF3R-T618I-positive aCML with a robust
clinical response to JAK1/2 inhibition with ruxolitinib. The clinical
beneﬁt in this case was not merely leukoreduction but also improved
marrow function as evident by near normalization of Hgb, MCV, and
platelet counts. In addition, the patient had a signiﬁcant reduction in
spleen volume and constitutional symptoms, which were refractory to
hydroxyurea. In the report byMaxson et al. [3] a clinical case of CSF3R-
T618I-positive CNL was described where the patient also had platelet
and Hgb improvement with ruxolitinib. These clinical cases suggest
interesting differences between myeloﬁbrosis (primary, post-
polycythemia vera, and post-essential thrombocytosis) and CNL/aCML.
As noted in the Comfort I study, a randomized placebo-controlled
phase III clinical trial with ruxolitinib in patients with myeloﬁbrosis,
(1) thrombocytopenia is a dose-limiting toxicity, (2) WBC is not
substantially reduced in myeloﬁbrosis patients, and (3) marrow
function is not measureably improved with ruxolitinib despite
clinical responses (spleen and symptom reduction). One similarity
is that the allele burden of the oncogenic driver is not signiﬁcantly
reduced with ruxolitinib [8].
The case described here suggests that targeting JAK1/2 in
CNL/aCML may provide clinical beneﬁt beyond spleen and symptom
reduction, and may suppress the malignant clone and enhance
normal hematopoiesis more effectively than that seen in myeloﬁ-
brosis. Interestingly, we did not detect a reduction in CSF3R-T618I
allele frequency or overall bone marrow cellularity after 3 months of
treatment, suggesting that JAK1/2 inhibition may preferentially affect
cells not in the sanctuary of the bone marrow microenvironment. It
will be important to expand upon prior work to conﬁdently show
that speciﬁc inhibition of JAK kinases rather than other kinase targets
underlie these clinical responses. The safety proﬁle and clinical
beneﬁt of ruxolitinib treatment or other JAK1/2 inhibitors in patients
with CNL and aCML in a prospective clinical trial is needed to
establish the (1) frequency of clinical responses, (2) durability and
depth of clinical responses, (3) genetic modiﬁers of disease char-
acteristics and clinical responses such as co-existing SETBP1 or TET2
mutations, and (4) impact on long-term quality of life and overall
survival. As of this report, a prospective, multi-center phase II clinical
trial investigating the safety and efﬁcacy of ruxolitinib in this patient
population is registered at ClinicalTrials.gov (NCT02092324) and is
open for participant recruitment.
In summary, this case highlights the potential clinical beneﬁt of
JAK1/2 inhibition for patients with CNL or aCML with CSF3R muta-
tions. It is not known yet whether patients with wildtype CSF3R will
experience the same clinical beneﬁt. Many patients with CNL and
aCML present with severe anemia and thrombocytopenia thus limiting
the usefulness of hydroxyurea. The recent discovery of frequent
mutations in CSF3R in patients with CNL and aCML and the preclinical
studies supporting JAK1/2 as a molecular target have uncovered a
potential line of therapy for these rare types of leukemia associated
with very poor prognosis.
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Immature granulocytesa o10% Z10%
Myeloblasts o1% o20%
Marrow
Granulocytic hyperplasia Present Present
Myeloblasts o5% o20%
Granulocytic dysplasia Minimal/absent Present
Megakaryocytic dysplasia Absent Present
a Promyelocytes, myelocytes, and metamyelocytes.
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Fig. 1. Clinical response in a patient with CSF3R-T618I-positive aCML treated with ruxolitinib. (A) WBC, platelet, Hgb, and MCV laboratory values during ruxolitinib treatment.
Refer to case study description for details. Hydroxyurea was stopped at the indicated red circle and ruxolitinib was started at 10 mg twice daily at the indicated green triangle,
both on the x-axis. Subsequent green triangles indicate when ruxolitinib was increased to 15 mg twice daily, then to 20 mg twice daily. (B) Spleen volume was determined by
conventional prolate ellipsoid method (0.524W TML; width, thickness, and max length). Two different ultrasound views are shown, the transverse and longitudinal
views. Before ruxolitinib treatment, the spleen was diffusely echogenic with hyperechoic nodules. The spleen measured 25.619.516.6 cm; volume¼4342 cm3. After
3 months of ruxolitinib treatment, the spleen was normal in echogenicity and the hyperechoic nodules resolved. The spleen measured 18.514.37.6 cm; volume¼1053 cm3.
(C) Shown is the MPN-SAF symptom questionnaire as ﬁlled out by the patient. The total symptom score (the sum of each line) is quantitative and a useful tool to monitor
symptoms and treatment responses [7]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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